Cheever Martin A, Schlom Jeffrey, Weiner Louis M, Lyerly H Kim, Disis Mary L, Greenwood Addison, Grad Oren, Nelson William G
Fred Hutchinson Cancer Research Center, Seattle, Washington, USA.
Clin Cancer Res. 2008 Sep 15;14(18):5692-9. doi: 10.1158/1078-0432.CCR-08-1266.
The Translational Research Working Group (TRWG) was created as a national initiative to evaluate the current status of the investment of National Cancer Institute in translational research and envision its future. The Translational Research Working Group conceptualized translational research as a set of six developmental processes or pathways focused on various clinical goals. One of those pathways describes the development of immune response modifiers such as vaccines and cytokines. A hallmark of the Immune Response Modifier Developmental Pathway is the coordinated development of multiple components. The Immune Response Modifier Pathway was conceived not as a comprehensive description of the corresponding real-world processes but rather as a tool designed to facilitate movement of a candidate assay through the translational process to the point where it can be handed off for definitive clinical testing. This paper discusses key challenges associated with the immune response modifier agent development process in light of the pathway.
转化研究工作组(TRWG)作为一项全国性倡议而成立,旨在评估美国国立癌症研究所(National Cancer Institute)在转化研究方面的投资现状并展望其未来。转化研究工作组将转化研究概念化为一组围绕各种临床目标的六个发展过程或途径。其中一条途径描述了免疫反应调节剂(如疫苗和细胞因子)的开发。免疫反应调节剂开发途径的一个标志是多个组成部分的协同发展。免疫反应调节剂途径并非旨在全面描述相应的现实世界过程,而是作为一种工具,旨在促进候选检测方法在转化过程中推进,直至能够移交进行确定性临床试验。本文根据该途径讨论了与免疫反应调节剂开发过程相关的关键挑战。